Day 2: Thursday, September 24Thursday, 24 September 2026

• Outlining the apelin pathway as a therapeutic target to replicate the benefits of exercise through small molecule agonists.

• A preclinical overview, including incretin-based co-administration

Please contact Roshni Shah for more information: Roshni.shah@informa.com

• The current obesity treatment landscape highlights the need for clinically and commercially sustainable weight loss solutions, with improved tolerability to support patient adherence and enable long-term use.
• Aphaia is developing a novel glucose-based formulation that restores the physiological release of gastrointestinal hormones involved in glucose metabolism and appetite regulation, as demonstrated in Phase 1 and 2 studies, with a strong tolerability profile observed to date.
• Presenting results from a Phase 2 trial evaluating Aphaia’s formulation in individuals with obesity, conducted without concomitant lifestyle changes, calorie restrictions, or coaching, and discuss its potential position in the current treatment landscape.

Please contact Roshni Shah for more information: Roshni.shah@informa.com

• Exploring precise incorporation of non-canonical amino acids to create GLP-1 peptides with enhanced stability and improved pharmacokinetics

• Exploring an oral-based SARM (Selective Androgen Receptor Modulator), Enobosarm, to prevent muscle moss in older obese patients using GLP-1 agonists for weight loss

Please contact Roshni Shah for more information: Roshni.shah@informa.com

• Investigating monoclonal antibody targeting of INBHE and myostatin, and further application to GLP-1 combined therapies

• Updates on novel antibody-based strategy targeting amylin

• Exploring the potential of combined anti-myostatin and anti-activin A therapeutics as solution to preserve lean muscle mass for patients undertaking incretin-based therapeutics for weight-loss

• Reviewing recent trials in the neuroprotective potential of GLP-1 based therapeutics for Alzhiemers’ disease, and exploring future directions for application to neurogenerative diseases

• Reviewing the effects of GLP-1 based therapies on insulin resistance, MASH/MetALD, dyslipidemia and CKM syndrome in rodent models
• Expanding the preclinical toolkit: Exploring GLP-1 therapeutic potential in emerging models of HFpEF, aging, and female-specific cardiometabolic phenotypes.

• Leveraging bariatric bypass clinical insights with novel oral small-molecule pharmaceuticals
• Synergy with rapidly evolving metabolic armamentarium
• Well-tolerated and effective early treatment choice alongside metformin and SGLT2s while complementing incretin-based therapies
• Looking towards boarder applications, including MASH and PCOS

• Addressing the challenges of securing reimbursement for obesity treatments by engaging with diverse payer systems, while advocating for the recognition of obesity as a chronic disease requiring essential care.

• Analysing the differences in pricing models and reimbursement frameworks between the US and Europe, reflecting on the progress made by 2026, identifying pitfalls, and outlining actionable steps for 2027 to enhance patient access.

• Exploring how biotech and pharma can drive innovation to develop affordable, scalable obesity treatments that balance cutting-edge science with accessibility